Respironics Has Sweet Dreams In November As Stock Advances
This article was originally published in The Gray Sheet
Executive Summary
Increased investor visibility, strong obstructive sleep apnea sales and a smooth CEO transition helped Respironics achieve a 9.2% stock gain in November